Search Results - Llorin-Sangalang, J

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    ZANDELISIB, A PI3Kδ INHIBITOR ON INTERMITTENT SCHEDULE (IS) IN FOLLICULAR LYMPHOMA PATIENTS WHO PROGRESSED WITHIN 24 MONTHS OF FIRST‐LINE CHEMOIMUNOTHERAPY (POD24)

    ZANDELISIB, A PI3Kδ INHIBITOR ON INTERMITTENT SCHEDULE (IS) IN FOLLICULAR LYMPHOMA PATIENTS WHO PROGRESSED WITHIN 24 MONTHS OF FIRST‐LINE CHEMOIMUNOTHERAPY (POD24) by Pagel, J., Reddy, N., Jagadeesh, D., Stathis, A., Asch, A. S., Salman, H., Kenkre, V. P., Soumerai, J. D., Llorin‐Sangalang, J., Gorbatchevsky, I., Li, J., Zelenetz, A. D.

    Published in Hematological oncology
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    THE PI3Kδ INHIBITOR ME‐401 ± RITUXIMAB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND SMALL LYMPHOCYTIC LYMPHOMA (SLL)

    THE PI3Kδ INHIBITOR ME‐401 ± RITUXIMAB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND SMALL LYMPHOCYTIC LYMPHOMA (SLL) by Zelenetz, A.D., Jagadeesh, D., Kenkre, V.P., Reddy, N.M., Stathis, A., Salman, H.S., Asch, A.S., Soumerai, J., Jhangiani, H.S., Iasonos, A., Patel, K., Carter, J., LLorin‐Sangalang, J., Pagel, J.M.

    Published in Hematological oncology
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    A PIVOTAL, RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED, TWO‐ARM, PHASE 2 STUDY OF ME‐401 INVESTIGATING TWO DOSING SCHEDULES IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) AFTER FAILURE OF TWO OR MORE PRIOR SYSTEMIC THERAPIES

    A PIVOTAL, RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED, TWO‐ARM, PHASE 2 STUDY OF ME‐401 INVESTIGATING TWO DOSING SCHEDULES IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) AFTER FAILURE... by Zelenetz, A., Zinzani, P., Buske, C., Ribrag, V., Cunningham, D., Jurczak, W., Abrisqueta, P., Agajanian, R., Chaudhry, A., Kayyal, T., Wood, J., Llorin‐Sangalang, J., Brown, J.

    Published in Hematological oncology
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Abstract OT3-06-01: SHERBOC: A double-blind, placebo-controlled, phase 2 trial of seribantumab (MM-121) plus fulvestrant in postmenopausal women with hormone receptor-positive, heregulin positive, HER2 negative metastatic breast cancer whose disease progressed after prior systemic therapy

    Abstract OT3-06-01: SHERBOC: A double-blind, placebo-controlled, phase 2 trial of seribantumab (MM-121) plus fulvestrant in postmenopausal women with hormone receptor-positive, her... by Kaufman, PA, Pipas, M, Finn, GJ, Mathews, SE, Zhang, H, Richards, J, Kudla, AJ, Bloom, T, Zalutskaya, AA, Llorin-Sangalang, J, Pinto, AC, Ettl, J

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: